

Filed On Behalf Of:
Novartis Pharmaceuticals Corporation

By:
Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner.

Case IPR2017-01592

Patent No. 8,410,131

**PATENT OWNER'S PRELIMINARY
RESPONSE UNDER 37 C.F.R. § 42.107**

TABLE OF CONTENTS

I.	Introduction.....	1
II.	POSA And Invention Date	3
III.	Claim Construction.....	3
	A. “Solid Excretory System Tumors”	4
	1. Patent Owner’s Construction Is Supported By The Specification And The Ordinary And Customary Meaning	4
	2. Breckenridge’s Proposed Construction Is Incorrect	7
	B. “Advanced Solid Excretory System Tumor[s]”	8
	C. “Kidney Tumor”	9
	D. Other Claim Terms	10
IV.	Breckenridge Fails To Show That The Priority Documents Lack Written Description Support For The ’131 Patent Claims	10
	A. The ’131 Patent Claims Are Entitled To The February 19, 2001 Priority Date Of GB ’072	13
	1. “Solid Excretory System Tumors”	13
	2. “Advanced Solid Excretory System Tumor[s]”	16
	3. “Kidney Tumor[s]”	17
	B. Breckenridge’s Flawed Analysis Elevates Form Over Substance.....	18
V.	The Board Should Deny Institution On Grounds 1-2 Because Wasik Does Not Anticipate Or Render Obvious The Challenged Claims.....	21
	A. Wasik Did Not Disclose Solid Tumors	21

1.	Wasik Disclosed Only Lymphomas	22
2.	The Prosecution Histories Of The '131 Patent Family Members And Of Wasik Confirm That Wasik Disclosed Only Lymphomas	24
3.	The Portions Of Wasik Upon Which Breckenridge Relies Disclosed Only Lymphomas.....	25
4.	Wasik Did Not Incorporate By Reference Any Teachings Concerning Solid Tumors	27
B.	Wasik Did Not Disclose Inhibiting Growth Of Advanced Tumors.....	30
C.	Wasik Did Not Render Obvious Any Challenged Claim	32
VI.	The Board Should Deny Institution On Grounds 2-5 Because Breckenridge Has Failed To Show A Motivation To Select Everolimus To Treat Solid Excretory System Tumors	33
VII.	The Board Should Deny Institution On Grounds 3-5 Because Breckenridge Has Failed To Show A Motivation To Combine The Rapamycin Art With The Everolimus Art Or A Motivation To Combine The Temsirolimus Art With The Everolimus Art	37
A.	None Of The References In Ground 3 Disclosed That Rapamycin And Everolimus Have The Same Mechanism Of Action For Antitumor Activity	39
B.	None Of The References In Ground 4 Disclosed That Temsirolimus And Everolimus Have The Same Mechanism Of Action For Antitumor Activity.....	41
C.	None Of The References In Ground 5 Disclosed That Temsirolimus And Everolimus Have The Same Mechanism Of Action For Antitumor Activity.....	43
D.	Everolimus, Unlike Temsirolimus, Was Known To Have Immunosuppressant Activity, Which Was Associated With Increased Rates Of Kidney Cancer	44

VIII. The Board Should Deny Institution On Ground 3 And Ground 5 Because Breckenridge Fails To Establish That Luan Is Prior Art	45
A. Breckenridge Has Not Shown That Luan Published In May 2001	46
B. Luan Did Not Publish Before The '131 Patent's Priority Date.....	49
C. Luan Is Antedated By GB '072.....	50
1. Prior Invention And Constructive Reduction To Practice.....	50
2. Luan Is Antedated Because GB '072 Shows Prior Invention Of At Least As Much Of The Claimed Invention As Is Shown By Luan.....	51
IX. Constitutionality Of <i>Inter Partes</i> Review.....	52
X. Conclusion	53

TABLE OF AUTHORITIES

Cases

<i>Alcon Research Ltd. v. Barr Labs., Inc.</i> , 745 F.3d 1180 (Fed. Cir. 2014)	21
<i>Ashland Oil, Inc. v. Delta Resins & Refractories, Inc.</i> , 776 F.2d 281 (Fed. Cir. 1985)	31
<i>Bilstad v. Wakalopulos</i> , 386 F.3d 1116 (Fed. Cir. 2004)	12
<i>Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.</i> , IPR2015-01850 <i>et al.</i> (Patent Tr. & App. Bd. Mar. 9, 2017), Paper 72	38, 46
<i>Coalition for Affordable Drugs V LLC v. Hoffman-LaRoche Inc.</i> , IPR2015-01792 (Patent Tr. & App. Bd. Mar. 11, 2016) Paper 14	37
<i>Cordis Corp. v. Medtronic AVE, Inc.</i> , 339 F.3d 1352 (Fed. Cir. 2003)	13
<i>Cuozzo Speed Techs., LLC v. Lee</i> , 136 S. Ct. 2131 (2016).....	4
<i>Eli Lilly & Co. v. Actavis Elizabeth LLC</i> , 731 F. Supp. 2d 348 (D.N.J. 2010).....	34
<i>Eli Lilly & Co. v. Actavis Elizabeth LLC</i> , 435 Fed. App'x 917 (Fed. Cir. 2011)	34
<i>Eli Lilly & Co. v. Sicor Pharms., Inc.</i> , 705 F. Supp. 2d. 971 (S.D. Ind. 2010).....	51, 52
<i>Ex Parte Saito</i> , Appeal 2008-5777, 2008 WL 5371879 (B.P.A.I. Dec. 22, 2008).....	50
<i>Fitbit, Inc. v. BodyMedia, Inc.</i> , IPR2016-00707 (Patent. Tr. & App. Bd. Sept. 8, 2016), Paper 9	11
<i>Frazer v. Schlegel</i> , 498 F.3d 1283 (Fed. Cir. 2007)	51

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.